It rarely covers them for other non-diabetes indications
In response to growing criticism of the cost of their drugs, Novo Nordisk, the company that manufactures Ozempic and Wegovy, reported last year that rebates and other fees (across all payers) accounted for about 40% of the cost of the two drugs and that they expected rebates to grow
That creates a simple opportunity for you: partner with turnkey telehealth providers who handle the medical heavy lifting, pharmacy dispensing, compliance, and even go to market support
For researchers weighing Swiss Chems alternatives on a risk-adjusted basis, this regulatory profile is relevant
Conversation & Assessment: We review your medical history, goals, and what has (and hasnt) worked for you in the past